Q1 FY27 results analysis · July 24, 2026
Dr Lal Pathlabs Ltd (LALPATHLAB) Q1 FY27 Results Analysis: PAT Jumps 28%, Acquisition Spree Continues
+28.0%PAT year on year, Rs. 169.50 Cr
Quick summary
Dr Lal Pathlabs Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 797.70 Cr (+19.10% YoY) and PAT growth of +28.02% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details
| Results date | July 24, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 797.70 Cr (+19.10% YoY) |
| PAT (Q1) | Rs. 169.50 Cr (+28.02% YoY) |
| EBITDA margin | 31.03% (+232 bps YoY) |
| EPS (Q1) | Rs. 10.15 (+27.83% YoY) |
| Market cap | Rs. 29,497.83 Cr |
| CMP | Rs. 1,759.20 |
Quarter Snapshot
Q1 revenue grew 19.1% YoY to Rs.797.7 Cr, with EBITDA margin expanding 232 bps to 31.0%. PAT attributable to owners rose 28% YoY. The company completed one acquisition and proposed another, expanding its network, though the sustainability of the elevated margin remains to be seen.
Key Investment Insights
Key Positives
- Revenue grew 19.1% YoY to Rs.797.7 Cr, accelerating from FY26 run-rate of ~12%.
- EBITDA margin expanded 232 bps YoY to 31.03%.
- PAT attributable to owners grew 28.02% YoY to Rs.169.5 Cr.
- Employee benefits ratio compressed 192 bps YoY to 16.64% of revenue.
- Acquisition of Shahbazkers Diagnostic Centre completed, expanding network.
- Proposed acquisition of 80% stake in Sunshine Healthcare (Ghana) for up to Rs.380 Mn.
Risk Factors
- Channel-partner fee ratio edged up to 14.52% from 14.30% YoY, a potential margin drag if growth slows.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Companies on this page
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.